1. ABSTRACT BRAF is a cytoplasmic serine-threonine protein kinasethat plays a critical role
in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by …

The BRAF V600E mutation is closely linked to tumorigenesis and malignant phenotype of
papillary thyroid cancer. Signaling pathways activated by BRAFV600E are still unclear …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Mutations in the BRAF gene are highly prevalent in thyroid cancer. However, the response
rate of thyroid tumors to BRAF‐directed therapies has been mixed. Increasingly …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Activating mutations of the BRAF gene are the most common genetic alterations in papillary
thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF V600E …

Context: Mutations in BRAF are rare in the follicular variant of papillary thyroid carcinoma
(FV-PTC). Objective: We identified and functionally characterized a novel T599I-VKSR (600 …

Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid
cancers (PTCs) that are locally invasive and have well-defined foci of poorly differentiated …

Somatic mutations in BRAF, especially BRAFV600E, are frequently identified in papillary
thyroid cancer (PTC) tumors. It has been established that expression levels of numbers of …